3.03 The National Lung Matrix Trial & the Major Flaw of the SPRINT Trial with Dr. Mark Friedberg

OncologyMedicineHealth Policy
Written By Kerrington .

This week we discuss two major papers: The first was just recently released in Nature and it's titled "The National Lung Matrix Trial of personalized therapy in lung cancer". The second is a few years old, but exemplifies the importance of trial design. We discuss the second paper, titled "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" and published in the New England Journal of Medicine with Dr. Mark Friedberg, a health policies and performance measurement researcher.

Kerrington .
Previous

3.04 Listener Questions & MedTwitter and Risk-Benefit Profile of Ramucirumab with Dr. Bishal Gyawali
Next

3.02 BONUS! National Clinician Scholars Program with Dr. Hilary Seligman